Juan Rico1, Luis Javier Echevarría-González de Garibay2, María García-López3, Sandra Guardiola-Vilarroig1,4, Luis Alberto Maceda-Roldán5, Óscar Zurriaga1,4,6, Clara Cavero-Carbonell7. 1. Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencia Region, Valencia, Spain. 2. Directorate for Healthcare Planning, Organization and Evaluation, Registries and Health Information Unit, Ministry of Health of the Basque Government, Vitoria-Gasteiz, Spain. 3. Rare Diseases Registry, Public Health Office, Castilla and León Government, Valladolid, Spain. 4. Public Health Regional Health Administration (DG Salud Publica y Adicciones), Generalitat Valenciana, Valencia, Spain. 5. Murcia Region Rare Diseases Information System, Murcia Regional Health Council, Murcia, Spain. 6. Public Health and Preventive Medicine Department, University of Valencia, Valencia, Spain. 7. Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencia Region, Valencia, Spain. cavero_cla@gva.es.
Abstract
BACKGROUND: Rare diseases present a wide spectrum of clinical manifestations and severity levels and are often poorly known and underrepresented, making them difficult to classify. Diagnoses are usually coded using the International Classification of Diseases (ICD), with its different versions. In Spain, the ICD-10-ES (stem from the ICD-10-CM-Clinical Modification) is used throughout the National Healthcare System since 2016, indistinctively including rare diseases that often lack a specific code. Orphanet aims to provide high-quality resources on rare diseases. The goal was to interrelate the Orphanet classification with the ICD-10-ES in order to engage a tool to track rare diseases diagnosis and characterize the improvement space for the identification of rare diseases patients in the Spanish Healthcare System. METHODS: 5775 disorder level ORPHAcodes were mapped to ICD-10-ES codes by comparing the descriptors associated in both classifications. ORPHAcodes were then clustered based on their assigned ICD-10-ES chapter and the redundancy of each individual ICD-10-ES code was calculated by counting the ORPHAcodes they mapped to. Three groups were established: Group 1 (1 ORPHAcode per ICD-10-ES), Group 2 (between 2-49 ORPHAcodes per ICD-10-ES) and Group 3 (≥ 50 ORPHAcodes per ICD-10-ES). RESULTS: Equivalences to 1700 ICD-10-ES codes were established for 5664 ORPHAcodes. The ORPHAcodes distribution within the ICD-10-ES showed an aggregation in the "Q" (> 40%), "G" (> 14%), and "E" (12%) chapters. The availability of ICD-10-ES codes to map ORPHAcodes reached its lowest at the "G" and "Q" chapters with less than 0.2 ICD-10-ES codes available per ORPHAcode. Global ICD-10-ES codes redundancy analysis revealed that only 1055 of the equivalences pertain to group 1. Group 2 contained 3358 equivalences with 634 ICD-10-ES codes while 1322 equivalences were group 3 (11 ICD-10-ES). Within ICD-10-ES chapters, "G" and "Q" contained over 30% and 45% of their own equivalences in the highest redundancy level (group 3) respectively, but under 10% one to one equivalences each (group 1). CONCLUSIONS: ICD-10-ES codes have not enough specificity to identify rare diseases. Direct mapping between ICD and ORPHAcodes or the integration of ORPHAcodes at the healthcare system for diagnoses codification would enable better detection and epidemiological analysis of rare diseases.
BACKGROUND: Rare diseases present a wide spectrum of clinical manifestations and severity levels and are often poorly known and underrepresented, making them difficult to classify. Diagnoses are usually coded using the International Classification of Diseases (ICD), with its different versions. In Spain, the ICD-10-ES (stem from the ICD-10-CM-Clinical Modification) is used throughout the National Healthcare System since 2016, indistinctively including rare diseases that often lack a specific code. Orphanet aims to provide high-quality resources on rare diseases. The goal was to interrelate the Orphanet classification with the ICD-10-ES in order to engage a tool to track rare diseases diagnosis and characterize the improvement space for the identification of rare diseases patients in the Spanish Healthcare System. METHODS: 5775 disorder level ORPHAcodes were mapped to ICD-10-ES codes by comparing the descriptors associated in both classifications. ORPHAcodes were then clustered based on their assigned ICD-10-ES chapter and the redundancy of each individual ICD-10-ES code was calculated by counting the ORPHAcodes they mapped to. Three groups were established: Group 1 (1 ORPHAcode per ICD-10-ES), Group 2 (between 2-49 ORPHAcodes per ICD-10-ES) and Group 3 (≥ 50 ORPHAcodes per ICD-10-ES). RESULTS: Equivalences to 1700 ICD-10-ES codes were established for 5664 ORPHAcodes. The ORPHAcodes distribution within the ICD-10-ES showed an aggregation in the "Q" (> 40%), "G" (> 14%), and "E" (12%) chapters. The availability of ICD-10-ES codes to map ORPHAcodes reached its lowest at the "G" and "Q" chapters with less than 0.2 ICD-10-ES codes available per ORPHAcode. Global ICD-10-ES codes redundancy analysis revealed that only 1055 of the equivalences pertain to group 1. Group 2 contained 3358 equivalences with 634 ICD-10-ES codes while 1322 equivalences were group 3 (11 ICD-10-ES). Within ICD-10-ES chapters, "G" and "Q" contained over 30% and 45% of their own equivalences in the highest redundancy level (group 3) respectively, but under 10% one to one equivalences each (group 1). CONCLUSIONS:ICD-10-ES codes have not enough specificity to identify rare diseases. Direct mapping between ICD and ORPHAcodes or the integration of ORPHAcodes at the healthcare system for diagnoses codification would enable better detection and epidemiological analysis of rare diseases.
Entities:
Keywords:
Codification; Diagnoses; Healthcare; ICD-10-ES; ORPHAcode; Public Health; Rare diseases
Authors: Melissa Haendel; Nicole Vasilevsky; Deepak Unni; Cristian Bologa; Nomi Harris; Heidi Rehm; Ada Hamosh; Gareth Baynam; Tudor Groza; Julie McMurry; Hugh Dawkins; Ana Rath; Courtney Thaxon; Giovanni Bocci; Marcin P Joachimiak; Sebastian Köhler; Peter N Robinson; Chris Mungall; Tudor I Oprea Journal: Nat Rev Drug Discov Date: 2020-02 Impact factor: 84.694
Authors: Trevor Richter; Sandra Nestler-Parr; Robert Babela; Zeba M Khan; Theresa Tesoro; Elizabeth Molsen; Dyfrig A Hughes Journal: Value Health Date: 2015-08-18 Impact factor: 5.725
Authors: Estrella López-Martín; Beatriz Martínez-Delgado; Eva Bermejo-Sánchez; Javier Alonso; Manuel Posada Journal: Int J Environ Res Public Health Date: 2018-08-14 Impact factor: 3.390
Authors: Gopalakrishnan Venkat-Raman; Charles R V Tomson; Yongsheng Gao; Ronald Cornet; Benedicte Stengel; Carola Gronhagen-Riska; Chris Reid; Christian Jacquelinet; Elke Schaeffner; Els Boeschoten; Francesco Casino; Frederic Collart; Johan De Meester; Oscar Zurriaga; Reinhard Kramar; Kitty J Jager; Keith Simpson Journal: Nephrol Dial Transplant Date: 2012-11-22 Impact factor: 5.992
Authors: Silvia Baldacci; Michele Santoro; Anna Pierini; Lorena Mezzasalma; Francesca Gorini; Alessio Coi Journal: Int J Environ Res Public Health Date: 2022-06-21 Impact factor: 4.614